IMPORTANT
SAFETY
INFORMATION FULL
PRESCRIBING
INFORMATION PATIENT
INFORMATION MEDICAL
INFORMATION PATIENT
SITE

For some, artificial tears may not be enough

Xiidra® can help disrupt the chronic
inflammatory cycle of dry eye disease^1-5*

Explore how Xiidra can deliver lasting symptom relief in
as early as 2 weeks.^1†

TAKE A LOOK AT THE DATA HELP YOUR PATIENTS SAVE >

^†Xiidra reduced symptoms of eye dryness (based on EDS) at 2 weeks in 2 out of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.¹

For some, artificial tears may not be enough

Xiidra® can help disrupt the chronic
inflammatory cycle of dry eye disease^1-5*

Explore how Xiidra can deliver lasting symptom relief in as early as 2 weeks.^1†

Take a look at the data

HELP YOUR PATIENTS SAVE >

^†Xiidra reduced symptoms of eye dryness (based on EDS) at 2 weeks in 2 out of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.¹

^*Xiidra blocks LFA-1 on T cells from binding with ICAM-1 that may be overexpressed on the ocular surface in dry eye disease and may prevent formation of an immunologic synapse which, based on in vitro studies, may inhibit T-cell activation, migration of activated T cells to the ocular surface, and reduce cytokine release. The exact mechanism of action of Xiidra in dry eye disease is not known.^1,2,5

FOOTNOTES

Your patient’s eyes deserve a change

Consider prescribing Xiidra, a first-in-class Rx therapy indicated for the treatment of the signs and symptoms of dry eye disease.^1,6‡

^‡Xiidra is an LFA-1 antagonist for the treatment of dry eye disease.¹

Potential Lasting symptom relief that can start in as early as 2 weeks^†

Xiidra reduced symptoms of eye dryness (based on EDS) at 2 weeks in 2 out of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.¹

Check out the data

Help Address the signs of dry eye disease

In 3 out of 4 studies, Xiidra showed notable improvements in signs (based on ICSS) of dry eye disease.¹

Dive into the studies

Safety data in clinical trials¹

The adverse reactions of Xiidra were studied across 5 clinical trials.^§

see the data

access for your patients^¶

Significantly broader coverage for your Medicare patients: Xiidra is now covered for nearly 3 out of 4 Medicare Part D patients (approximately 70% as of 7/1/22).⁷

Xiidra has comparable or better coverage to Restasis for 88% of commercially insured patients.^8¶

^¶Based on Commercial Formulary Access in National and Regional Accounts on July 12, 2022.

SEE BROADER COVERAGE

^†The safety and efficacy of Xiidra were assessed in four 12-week, randomized, multicenter, double-masked, vehicle-controlled studies (N=2133). Patients were dosed twice daily. The mean age was 59 years (range, 19-97 years). The majority of patients were female (76%). Use of artificial tears was not allowed during the studies. The study end points included assessment of signs (based on Inferior fluorescein Corneal Staining Score [ICSS] on a scale of 0 to 4) and symptoms (based on patient-reported Eye Dryness Score [EDS] on a visual analogue scale of 0 to 100). Effects on symptoms of dry eye disease: a larger reduction in EDS favoring Xiidra was observed in all studies at day 42 and day 84. Xiidra reduced symptoms of eye dryness at 2 weeks (based on EDS) compared to vehicle in 2 out of 4 clinical trials. Effects on signs of dry eye disease: at day 84, a larger reduction in ICSS favoring Xiidra was observed in 3 out of the 4 studies.¹

^§In 5 clinical studies of dry eye disease with lifitegrast ophthalmic solution, 1401 patients received at least 1 dose of lifitegrast (1287 of whom received Xiidra). The majority of patients (84%) had up to 3 months of treatment exposure. One hundred-seventy patients were exposed to Xiidra for approximately 12 months. The most common adverse reactions (reported in 5-25% of patients) were instillation-site irritation, dysgeusia, and reduced visual acuity.¹

^¶Based on Commercial Formulary Access in National and Regional Accounts on January 18, 2022.

Thought leader perspectives

Approaching DED in Presurgical Patients

Richard L. Lindstrom, MD
Founder and Attending Surgeon Emeritus at Minnesota Eye Consultants
Chief Medical Ofﬁce and Board Member at TLC Laser Eye Centers
Dr. Lindstrom is a paid consultant for Novartis Pharmaceuticals Corporation, the maker of Xiidra.

Discover his preferred treatment and management plan for DED in patients who are presenting for surgery, from Dr. Richard Lindstrom, Founder and Attending Surgeon Emeritus at Minnesota Eye Consultants, Chief Medical Officer and Board Member at TLC Laser Eye Centers, Senior Lecturer and Trustee Emeritus of the Foundation at the University of Minnesota and Visiting Professor at the UC Irvine Gavin Herbert Eye Institute. Dr. Lindstrom is a paid consultant for Novartis.

See his strategy

XIIDRA patient case
studies

Patient case study: Melanie

Melanie was a long-time user of artificial tears, but that brought her temporary relief. Read her clinical story, including how her symptoms improved after starting treatment with Xiidra.

Read melanie’s story

Melanie was compensated for her time.

Patient case study: Ar’Tee

Ar’Tee believed his dry eye symptoms were new, but then learned there may be something more. Get the clinical details on Ar’Tee’s case, as well as what happened when he started treatment with Xiidra.

Dive into Ar’Tee’s journey

Ar’Tee was compensated for his time.

Watch the Video

Xiidra is a nonsteroid therapy specifically developed to treat dry eye disease^1,9

See the science behind Xiidra, which targets a key part of an inflammatory cascade and can help disrupt the inflammatory cycle in dry eye disease.^1,2,5,10,||

Watch the Video

^||Xiidra is an LFA-1 antagonist for the treatment of dry eye disease. The exact mechanism of action of lifitegrast in DED is not known.¹

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.

References

1. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2020.
2. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438-510.
3. US Food and Drug Administration. Code of Federal Regulations, Title 21, Volume 5 (21CFR349). Accessed July 12, 2022. https://www.accessdata.fda.gov/
scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=349&showFR=1
4. Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575-628.
5. Pflugfelder SC, Stern M, Zhang S, Shojaei A. LFA-1/ICAM-1 interaction as a therapeutic target in dry eye disease. J Ocul Pharmacol Ther. 2017;33(1):5-12.
6. US Food and Drug Administration. FDA approves new medication for dry eye disease. Published July 12, 2016. Accessed July 12, 2022. https://www.fda.gov/news-events/press- announcements/fda-approves-new-medication-dry-eye-disease
7. Data on file. DRF Fingertip Formulary® Novartis Pharmaceuticals Corp; July 2022.
8. Data on file. DRG Fingertip Formulary® incorporating Payer Sciences business rules as of July 12, 2022.
9. Zhong M, Gadek TR, Bui M, et al. Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye. ACS Med Chem Lett. 2012;3(3):203-206.
10. Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016;14(2):207-215.

References

1. Farrand KF, Fridman M, Stillman IÖ, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90-98.
2. Data on file. Jefferies Franchise Note. Equity Research Americas. Novartis Pharmaceuticals Corp; May 2017.
3. Dana R, Bradley J, Guerin A, et al. Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age United States health care system. Am J Ophthalmol. 2019;202:47-54.
4. Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575-628.
5. US Food and Drug Administration. Code of Federal Regulations, Title 21, Volume 5 (21CFR349). Accessed July 12, 2022. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=349&showFR=1
6. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438-510.
7. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276-283.
8. American Academy of Ophthalmology. Dry Eye Syndrome Preferred Practice Pattern®. Accessed July 12, 2022. https://www.aao.org/Assets/8bb0fe82-84c8-4020-89e6- e123667fb654/636777165099570000/dry-eye-syndrome-preferred-practice-pattern- 2018-pdf
9. Matossian C, McDonald M, Donaldson KE, Nichols KK, Maclver S, Gupta PK. Dry Eye Disease: Consideration for women’s health. J Womens Health (Larchmt). 2019;28(4):502-514.
10. Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease. Ophthalmology. 2017;124:S4-S13.
11. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2020.
12. Pflugfelder SC, Stern M, Zhang S, Shojaei A. LFA-1/ICAM-1 interaction as a therapeutic target in dry eye disease. J Ocul Pharmacol Ther. 2017;33(1):5-12.
13. Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016;14(2):207-215.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.

Xiidra® can help disrupt the chronicinflammatory cycle of dry eye disease1-5*

For some, artificial tears may not be enough

FOOTNOTES

Your patient’s eyes deserve a change

Potential Lasting symptom relief that can start in as early as 2 weeks†

Help Address the signs of dry eye disease

Safety data in clinical trials1

access for your patients¶

Thought leader perspectives

Approaching DED in Presurgical Patients

Patient case study: Melanie

Patient case study: Ar’Tee

Xiidra is a nonsteroid therapy specifically developed to treat dry eye disease1,9

Xiidra® can help disrupt the chronic
inflammatory cycle of dry eye disease^1-5*

Potential Lasting symptom relief that can start in as early as 2 weeks^†

Safety data in clinical trials¹

access for your patients^¶

Xiidra is a nonsteroid therapy specifically developed to treat dry eye disease^1,9